培美曲塞作为非鳞状非小细胞肺癌的一线治疗药物。
Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer.
机构信息
Thoracic-Oncology Unit 1st, Lung Diseases Department, San Camillo-Forlanini High Specialization Hospitals, Rome, Italy;
出版信息
Ther Clin Risk Manag. 2009;5:781-7. doi: 10.2147/tcrm.s3195. Epub 2009 Oct 12.
Abstract
Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.
摘要
培美曲塞是一种新型细胞毒性药物，已被确立为治疗非小细胞肺癌（NSCLC）二线药物的标准方案，并且与顺铂联合用于治疗恶性胸膜间皮瘤。该药已在众多 II 期和 III 期临床试验中与不同药物联合应用或单药治疗进行了研究。最近，培美曲塞已被批准与顺铂联合用于除鳞状细胞组织学以外的局部晚期或转移性 NSCLC 患者的一线治疗。其毒性可耐受，与其他 NSCLC 方案相似。正在进行一项 III 期、双盲、安慰剂对照研究，以评估培美曲塞诱导后的维持治疗。
相似文献
1
Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer.培美曲塞作为非鳞状非小细胞肺癌的一线治疗药物。
Ther Clin Risk Manag. 2009;5:781-7. doi: 10.2147/tcrm.s3195. Epub 2009 Oct 12.
2
Pemetrexed: a multitargeted antifolate.培美曲塞：一种多靶点抗叶酸药物。
Clin Ther. 2005 Sep;27(9):1343-82. doi: 10.1016/j.clinthera.2005.09.010.
3
4
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.培美曲塞联合最佳支持治疗维持治疗对比安慰剂联合最佳支持治疗用于培美曲塞联合顺铂诱导治疗后的晚期非鳞状非小细胞肺癌（PARAMOUNT）：一项双盲、III 期、随机对照临床试验。
Lancet Oncol. 2012 Mar;13(3):247-55. doi: 10.1016/S1470-2045(12)70063-3. Epub 2012 Feb 16.
5
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.PARAMOUNT试验：一项III期随机研究，在培美曲塞加顺铂一线诱导治疗晚期非鳞状非小细胞肺癌后，比较培美曲塞维持治疗与安慰剂的疗效。
Rev Recent Clin Trials. 2013 Mar;8(1):23-8. doi: 10.2174/15748871112079990040.
6
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.培美曲塞用于局部晚期或转移性非小细胞肺癌的维持治疗。
Health Technol Assess. 2010 Oct;14(Suppl. 2):33-9. doi: 10.3310/hta14suppl2/05.
7
Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.培美曲塞：新药。胸膜间皮瘤：首次令人鼓舞的试验。
Prescrire Int. 2005 Dec;14(80):212-4.
8
Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer.培美曲塞：其在晚期非鳞状非小细胞肺癌治疗中应用的综述
Drugs. 2009 Nov 12;69(16):2279-302. doi: 10.2165/11202640-000000000-00000.
9
Pemetrexed disodium for the treatment of NSCLC: an update.培美曲塞二钠治疗非小细胞肺癌：最新进展
Drugs Today (Barc). 2008 Sep;44(9):669-78. doi: 10.1358/dot.2008.44.9.1250412.
10
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.奥那珠单抗联合一线贝伐单抗或培美曲塞化疗方案治疗晚期非鳞状非小细胞肺癌的疗效与安全性
Clin Lung Cancer. 2017 Jan;18(1):50-59. doi: 10.1016/j.cllc.2016.09.013. Epub 2016 Oct 19.
引用本文的文献
1
Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories.抗癌药物超说明书用药的前沿观点：分类更新与类别探索
Front Pharmacol. 2024 Jun 4;15:1374549. doi: 10.3389/fphar.2024.1374549. eCollection 2024.
2
Clinical implications of PNA‑sequencing as a complementary test for EGFR mutation analysis in human lung cancer.肽核酸测序作为人肺癌表皮生长因子受体（EGFR）突变分析补充检测的临床意义
Oncol Lett. 2023 Nov 2;26(6):539. doi: 10.3892/ol.2023.14126. eCollection 2023 Dec.
3
Pemetrexed and cisplatin-induced linear hyperpigmentation of skin.培美曲塞和顺铂引起的皮肤线性色素沉着。
Med J Armed Forces India. 2020 Jul;76(3):353-355. doi: 10.1016/j.mjafi.2018.11.003. Epub 2019 Jan 11.
4
CD133 inhibition via autophagic degradation in pemetrexed-resistant lung cancer cells by GMI, a fungal immunomodulatory protein from Ganoderma microsporum.通过从灵芝 microsporum 中提取的真菌免疫调节剂 GMI 诱导自噬降解来抑制培美曲塞耐药的肺癌细胞中的 CD133
Br J Cancer. 2020 Aug;123(3):449-458. doi: 10.1038/s41416-020-0885-8. Epub 2020 May 25.
5
Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).在一线使用非铂类方案预处理的非小细胞肺癌患者中，伊立替康/顺铂与培美曲塞/顺铂挽救治疗的比较：希腊肿瘤学研究组（HORG）的一项随机II期研究
Clin Transl Oncol. 2017 Mar;19(3):317-325. doi: 10.1007/s12094-016-1532-y. Epub 2016 Aug 4.
6
Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma.脑转移肺腺癌患者中卡铂联合培美曲塞的 upfront 联合治疗。
Neuro Oncol. 2012 Apr;14(4):491-5. doi: 10.1093/neuonc/nos004. Epub 2012 Feb 22.
7
Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.培美曲塞联合顺铂/卡铂治疗既往治疗的局部晚期或转移性非小细胞肺癌患者。
J Exp Clin Cancer Res. 2010 Apr 27;29(1):38. doi: 10.1186/1756-9966-29-38.
本文引用的文献
1
Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.吉西他滨和顺铂快速序贯给药作为晚期非小细胞肺癌一线化疗的II期临床试验
Ann Oncol. 2009 May;20(5):850-6. doi: 10.1093/annonc/mdn715. Epub 2009 Jan 15.
2
The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review.组织学在晚期非小细胞肺癌中的预后及预测作用：文献综述
J Thorac Oncol. 2008 Dec;3(12):1468-81. doi: 10.1097/JTO.0b013e318189f551.
3
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.一项III期研究，比较顺铂加吉西他滨与顺铂加培美曲塞用于初治晚期非小细胞肺癌患者的化疗效果。
J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.
4
Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer.培美曲塞与吉西他滨每月两次给药用于晚期癌症和非小细胞肺癌患者的1/2期剂量递增研究。
J Thorac Oncol. 2008 Apr;3(4):394-9. doi: 10.1097/JTO.0b013e318169cdc4.
5
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.单药培美曲塞或序贯培美曲塞/吉西他滨作为老年患者或不符合铂类化疗条件患者晚期非小细胞肺癌的一线治疗：一项多中心、随机、II期试验。
J Thorac Oncol. 2007 Mar;2(3):221-9. doi: 10.1097/JTO.0b013e318031cd62.
6
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.单独使用紫杉醇-卡铂或联合贝伐单抗治疗非小细胞肺癌。
N Engl J Med. 2006 Dec 14;355(24):2542-50. doi: 10.1056/NEJMoa061884.
7
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.与其他组织学类型相比，肺鳞状细胞癌显示出胸苷酸合成酶的信使核糖核酸和蛋白质水平更高。
Cancer. 2006 Oct 1;107(7):1589-96. doi: 10.1002/cncr.22208.
8
Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.吉西他滨之后立即给予培美曲塞作为晚期非小细胞肺癌一线治疗：一项II期试验
Lung Cancer. 2006 Jul;53(1):77-83. doi: 10.1016/j.lungcan.2006.04.005. Epub 2006 May 30.
9
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.培美曲塞联合卡铂一线治疗晚期非小细胞肺癌的II期研究。
Cancer. 2005 Dec 1;104(11):2449-56. doi: 10.1002/cncr.21480.
10
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.培美曲塞与吉西他滨三种给药方案作为晚期非小细胞肺癌一线治疗的随机II期试验
J Clin Oncol. 2005 Sep 1;23(25):5929-37. doi: 10.1200/JCO.2005.13.953.
Zotero 插件